期刊论文详细信息
Genome Medicine
PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling
Haitao Li1  Zhi-Wei Jiang2  Hua-Feng Pan2  Jin Wang3  Ke Zen3  Xiangwei Zeng3  Ming Liu3  Peipei Xu3  Ruifeng Hu3  Yexuan Deng3  Ying Wang3  Tao Gui3  Bing Chen3  Junyi Ju3  Quan Zhao3  Qixiang Li3  Dongjun Yang3  Zhi Wang3  Xinyu Li3  Bing Yao4  David C. S. Huang5  Melissa J. Davis5  Marco J. Herold5 
[1] Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Tsinghua-Peking Joint Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, China;Department of General Surgery, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China;The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, 163 Xianlin Avenue, 210023, Nanjing, China;The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, 163 Xianlin Avenue, 210023, Nanjing, China;Department of Medical Genetics, Nanjing Medical University, Nanjing, China;The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia;
关键词: Transcription;    Epigenomics;    H4R3me2s;    PRMT1;    SMARCA4;    Colorectal Cancer;   
DOI  :  10.1186/s13073-021-00871-5
来源: Springer
PDF
【 摘 要 】

BackgroundAberrant changes in epigenetic mechanisms such as histone modifications play an important role in cancer progression. PRMT1 which triggers asymmetric dimethylation of histone H4 on arginine 3 (H4R3me2a) is upregulated in human colorectal cancer (CRC) and is essential for cell proliferation. However, how this dysregulated modification might contribute to malignant transitions of CRC remains poorly understood.MethodsIn this study, we integrated biochemical assays including protein interaction studies and chromatin immunoprecipitation (ChIP), cellular analysis including cell viability, proliferation, colony formation, and migration assays, clinical sample analysis, microarray experiments, and ChIP-Seq data to investigate the potential genomic recognition pattern of H4R3me2s in CRC cells and its effect on CRC progression.ResultsWe show that PRMT1 and SMARCA4, an ATPase subunit of the SWI/SNF chromatin remodeling complex, act cooperatively to promote colorectal cancer (CRC) progression. We find that SMARCA4 is a novel effector molecule of PRMT1-mediated H4R3me2a. Mechanistically, we show that H4R3me2a directly recruited SMARCA4 to promote the proliferative, colony-formative, and migratory abilities of CRC cells by enhancing EGFR signaling. We found that EGFR and TNS4 were major direct downstream transcriptional targets of PRMT1 and SMARCA4 in colon cells, and acted in a PRMT1 methyltransferase activity-dependent manner to promote CRC cell proliferation. In vivo, knockdown or inhibition of PRMT1 profoundly attenuated the growth of CRC cells in the C57BL/6 J-ApcMin/+ CRC mice model. Importantly, elevated expression of PRMT1 or SMARCA4 in CRC patients were positively correlated with expression of EGFR and TNS4, and CRC patients had shorter overall survival. These findings reveal a critical interplay between epigenetic and transcriptional control during CRC progression, suggesting that SMARCA4 is a novel key epigenetic modulator of CRC. Our findings thus highlight PRMT1/SMARCA4 inhibition as a potential therapeutic intervention strategy for CRC.ConclusionPRMT1-mediated H4R3me2a recruits SMARCA4, which promotes colorectal cancer progression by enhancing EGFR signaling.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO202110287212727ZK.pdf 4326KB PDF download
  文献评价指标  
  下载次数:15次 浏览次数:2次